Set of sgRNA capable of specifically recognizing pig CD163 gene as well as encoding DNA and application of sgRNA
By using a complete set of sgRNAs in the CRISPR/Cas9 system to edit the porcine CD163 gene, the problem of efficient editing of the porcine CD163 gene in existing technologies has been solved, enabling the breeding of new porcine breeds resistant to PRRSV infection.
Patent Information
- Application Number
- CN202310597179.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-25
- Publication Date
- 2024-11-26
AI Technical Summary
Existing technologies make it difficult to efficiently edit the porcine CD163 gene to breed new pig breeds resistant to porcine reproductive and respiratory syndrome virus (PRRSV) infection.
By using a set of sgRNAs (CD163-sgRNA1 and CD163-sgRNA2) from the CRISPR/Cas9 system to bind to the Cas9 protein, the sgRNAs specifically recognize and edit the seventh exon of the porcine CD163 gene, achieving efficient splicing.
The method achieves efficient editing of the porcine CD163 gene, significantly reducing the infection capacity of porcine cells against PRRSV. It has high editing efficiency and strong specificity, and can be used to breed new porcine breeds resistant to PRRSV infection.
Smart Images

Figure BDA0004247571270000081 
Figure HDA0004247571280000011 
Figure HDA0004247571280000012
Abstract
Description
Technical Field
[0001] The present invention relates to the field of genetic engineering technology, and in particular to a set of sgRNAs for specifically recognizing porcine CD163 genes and encoding DNA and applications thereof. Background Art
[0002] Porcine reproductive and respiratory syndrome is an infectious disease caused by porcine reproductive and respiratory syndrome virus (PRRSV), characterized by reproductive disorders in pregnant sows and respiratory symptoms in piglets. The disease was first discovered in North Carolina, USA, and has since been found in Canada, Germany, and the United Kingdom. In 1992, the International Veterinary Office named the disease porcine reproductive and respiratory syndrome (PRRS). Porcine reproductive and respiratory syndrome virus is a single-stranded positive-strand RNA virus with a high mutation frequency due to point mutations, deletions, insertions, and substitutions in the RNA genome. The epidemic of this disease was also reported in my country in 1996. In 2006, a mutated highly pathogenic PRRSV caused porcine reproductive and respiratory syndrome, which caused huge economic losses to the pig industry.
[0003] CD163 is a type I membrane protein of the B subfamily of the scavenger receptor cysteine-rich superfamily (SRCRs). Studies have shown that porcine CD163 protein plays a core receptor function in mediating type 1 and type 2 PRRSV infection, and there is a positive correlation between the expression of CD163 protein on the surface of porcine alveolar macrophages (PAMs) and the infection ability of PRRSV. Using genome editing technology to edit the CD163 gene of pigs is expected to breed new pig breeds that can resist PRRSV infection. Summary of the invention
[0004] The technical problem to be solved by the present invention is how to efficiently edit the porcine CD163 gene to cultivate a new breed of pigs resistant to PRRSV infection.
[0005] In a first aspect, the present invention protects a set of sgRNAs.
[0006] The set of sgRNAs protected by the present invention includes CD163-sgRNA1 and CD163-sgRNA2;
[0007] The nucleotide sequence responsible for identifying the target fragment in the CD163-sgRNA1 is shown in SEQ ID No. 1;
[0008] The nucleotide sequence responsible for recognizing the target fragment in the CD163-sgRNA2 is shown in SEQ ID No.2.
[0009] The sgRNA in the present invention is a guide RNA, which is an important component of the CRISPR gene knockout and knock-in system. It can bind to the Cas9 protein and guide the Cas9 protein to target genomic DNA for shearing.
[0010] In a specific embodiment of the present invention, the nucleotide sequence of the CD163-sgRNA1 is shown as SEQ ID No.5; the nucleotide sequence of the CD163-sgRNA2 is shown as SEQ ID No.6.
[0011] In a second aspect, the present invention protects a set of DNA molecules.
[0012] The set of DNA molecules protected by the present invention includes a DNA molecule encoding the CD163-sgRNA1 and a DNA molecule encoding the CD163-sgRNA2;
[0013] The DNA molecule encoding the CD163-sgRNA1 contains the DNA molecule shown in SEQ ID No.3;
[0014] The DNA molecule encoding the CD163-sgRNA2 contains the DNA molecule shown in SEQ ID No.4.
[0015] In a specific embodiment of the present invention, the DNA molecule encoding the CD163-sgRNA1 is shown in SEQ ID No. 7;
[0016] The DNA molecule encoding the CD163-sgRNA2 is shown in SEQ ID No.8.
[0017] In a third aspect, the present invention protects a set of vectors.
[0018] The set of vectors protected by the present invention includes a vector expressing the CD163-sgRNA1 and a vector expressing the CD163-sgRNA2;
[0019] The vector expressing the CD163-sgRNA1 is a vector containing the above-mentioned DNA molecule encoding CD163-sgRNA1;
[0020] The vector expressing the CD163-sgRNA2 is a vector containing the above-mentioned DNA molecule encoding CD163-sgRNA2.
[0021] The above-mentioned vector can be any common vector in the technical field, such as pT7-sgRNA vector or pX330 vector or pX458 vector, preferably pX330 vector.
[0022] In a specific embodiment of the present invention, the set of vectors consists of the pX330-CD163-sgRNA1 vector and the pX330-CD163-sgRNA2 vector in the examples below.
[0023] In another specific embodiment of the present invention, the set of vectors consists of the pX330-GFP-CD163-sgRNA1 vector and the pX330-RFP-CD163-sgRNA2 vector in the examples below.
[0024] In a fourth aspect, the present invention protects a kit comprising the above-mentioned set of sgRNA or the above-mentioned set of DNA molecules or the above-mentioned set of vectors.
[0025] Furthermore, the kit also includes Cas9 protein or biological materials related to the Cas9 protein.
[0026] The biological material related to the Cas9 protein may be a nucleic acid molecule encoding the Cas9 protein or an expression cassette or a recombinant vector containing the nucleic acid molecule.
[0027] The above-mentioned Cas9 protein can be a conventional Cas9 protein, such as the Cas9 protein shown in GenBank as ANW61896.1, or it can be a Cas9 protein modified by molecular biology, as long as it has the cutting function of the Cas9 protein.
[0028] The above-mentioned nucleic acid molecule encoding the Cas9 protein may be a DNA or RNA encoding the Cas9 protein.
[0029] The above-mentioned expression cassette containing the nucleic acid molecule encoding the Cas9 protein refers to a DNA capable of expressing the Cas9 protein in a host cell, and the DNA may include not only a promoter for initiating transcription of the Cas9 gene, but also a terminator for terminating transcription of the Cas9 gene.
[0030] The above-mentioned recombinant vector containing a nucleic acid molecule encoding the Cas9 protein refers to a vector containing a nucleic acid molecule encoding the Cas9 protein.
[0031] Furthermore, the vector is the pX330-CD163-sgRNA1 vector in the following examples, or the pX330-CD163-sgRNA2 vector in the following examples, or the pX330-GFP-CD163-sgRNA1 vector in the following examples, or the pX330-RFP-CD163-sgRNA2 vector in the following examples.
[0032] In a fifth aspect, the present invention protects new uses of the above-mentioned set of sgRNA or the above-mentioned set of DNA molecules or the above-mentioned set of vectors or the above-mentioned kit.
[0033] The present invention protects the use of the above-mentioned set of sgRNA or the above-mentioned set of DNA molecules or the above-mentioned set of vectors or the above-mentioned kit in any of the following 1)-5):
[0034] 1) CD163 gene editing in the pig genome;
[0035] 2) Prepare products for CD163 gene editing in the pig genome;
[0036] 3) Preparation of CD163 gene-edited pig-derived cells;
[0037] 4) Preparation of CD163 gene-edited pigs;
[0038] 5) Breed pig breeds that are resistant to PRRSV infection.
[0039] In a sixth aspect, the present invention protects any one of the following methods A1)-A8):
[0040] A1) A method for CD163 gene editing in a pig genome, comprising the step of introducing the above-mentioned set of sgRNA or the above-mentioned set of vectors and Cas9 protein into a pig-derived biomaterial;
[0041] A2) A method for preparing CD163 gene-edited pig-derived cells, comprising the step of introducing the above-mentioned set of sgRNA or the above-mentioned set of vectors and Cas9 protein into pig-derived cells;
[0042] A3) A method for preparing a CD163 gene-edited pig, comprising the step of introducing the above-mentioned set of sgRNA or the above-mentioned set of vectors and Cas9 protein into a pig-derived biomaterial;
[0043] A4) A method for preparing a pig breed resistant to PRRSV infection, comprising the step of introducing the above-mentioned set of sgRNA or the above-mentioned set of vectors and Cas9 protein into a pig-derived biological material;
[0044] A5) a method for editing the CD163 gene in the pig genome, comprising the step of deleting the base sequence of position 148-267 of the seventh exon of the pig CD163 gene in the pig-derived biological material;
[0045] A6) A method for preparing CD163 gene-edited pig-derived cells, comprising the step of deleting the base sequence at positions 148-267 of the seventh exon of the pig CD163 gene in the pig-derived cells;
[0046] A7) A method for preparing a CD163 gene-edited pig, comprising the step of deleting the base sequence at positions 148-267 of the seventh exon of the pig CD163 gene in a pig-derived biological material;
[0047] A8) The preparation method of the pig variety that resists PRRSV infection comprises the step of deleting the base sequence of position 148-267 of the seventh exon of the pig CD163 gene in the pig source biological material.
[0048] In any of the above methods, the deletion is a homozygous deletion, that is, the deletion occurs in both homologous chromosomes.
[0049] In any of the above-mentioned applications or methods, the CD163 gene-edited pig can be prepared as follows: CD163 gene-edited pig-derived cells are used as nuclear transplant donor cells, and in vitro matured young pig oocytes are used as nuclear transplant recipient cells. The nuclear transplant donor cells are transferred into the enucleated oocytes, and then electrofusion and activation are performed to construct recombinant cloned embryos, and then cloned recombinant embryos with good development status are selected and surgically transferred into the uterus of a naturally estrus multiparous large white sow for pregnancy, and finally the CD163 gene-edited pig is obtained after screening and identification. The identification method can be sequencing identification, specifically, the DNA of the CD163 gene-edited pig can be extracted, and then PCR amplification is performed using primers shown in SEQ ID No. 10 and SEQ ID No. 6), and then the amplified product is sequenced to confirm whether precise editing is achieved.
[0050] In any of the above applications or methods, the porcine biological material includes porcine cells or porcine embryos. The porcine cells may specifically be porcine fetal fibroblasts or porcine alveolar macrophages.
[0051] In any of the above applications or methods, the pig is a Large White pig.
[0052] In any of the above-mentioned applications or methods, the CD163 gene is the seventh exon of the CD163 gene, and the nucleotide sequence of the seventh exon of the CD163 gene is shown in SEQ ID No.9.
[0053] The present invention proves through experiments that the set of sgRNA provided by the present invention can specifically recognize the seventh exon of the porcine CD163 gene, and the set of sgRNA combined with the Cas9 protein can efficiently edit the porcine CD163 gene, has the advantages of high editing efficiency and strong specificity, and can modify the seventh exon of the porcine CD163 gene through the CRISPR / Cas9 system, which is of great value in the study of the function of the porcine CD163 gene and the breeding of new pig varieties resistant to PRRSV infection. BRIEF DESCRIPTION OF THE DRAWINGS
[0054] Figure 1 The results of fluorescence quantitative PCR (qRT-PCR) detection of PRRSV RNA copy number after PRRSV infection in iPAM cells with 120bp precise fragment deletion of CD163 gene provided in Example 2 of the present invention.
[0055] Figure 2 The results of protein immunoblotting (Western Blot) detection of CD163 and PRRSV-N protein expression in iPAM cells with 120 bp precise fragment deletion of the CD163 gene provided in Example 2 of the present invention after PRRSV infection.
[0056] Figure 3 The indirect immunofluorescence (IFA) detection of PRRSV-N protein expression in the CD163 gene 120bp precise fragment deleted iPAM cells after PRRSV infection provided in Example 2 of the present invention.
[0057] Figure 4 This is the genotype of CD163 gene in porcine fetal fibroblasts after editing. DETAILED DESCRIPTION
[0058] The present invention is further described in detail below in conjunction with specific embodiments, and the examples provided are only for illustrating the present invention, rather than for limiting the scope of the present invention. The examples provided below can be used as a guide for further improvements by those of ordinary skill in the art, and do not constitute a limitation of the present invention in any way.
[0059] The experimental methods in the following examples, unless otherwise specified, are all conventional methods, and are performed according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial channels.
[0060] The porcine alveolar macrophages (immortalized porcine alveolar macrophages, iPAM) in the following example are recorded in the document “Tong-Yun Wang et al. Porcine alveolar macrophage CD163 abundance is a pivotal switch for porcine reproductive and respiratory syndrome virus infection. Oncotarget, 2018, 9(15): 12174-12185”.
[0061] The preparation method of porcine fetal fibroblasts in the following example is as follows: the head, tail, limbs and internal organs of a 30-day-old Large White pig embryo are removed, the remaining tissues are fully minced and digested and then spread flat in a culture bottle, and the cells are frozen and stored for later use after full growth.
[0062] PRRSV-WUH3 (GenBank: HM853673) in the following examples is recorded in the document “Li B, et al. Recombination in vaccine and circulating strains of porcine reproductive and respiratory syndrome viruses. Emerging Infectious Diseases, 2009, 15: 2032-2035”.
[0063] The nucleotide sequence of the seventh exon of the porcine CD163 gene in the following examples is shown in SEQ ID No.9.
[0064] The amino acid sequence of the Cas9 protein in the following examples is ANW61896.1 in GenBank of NCBI.
[0065] Example 1. Preparation of a set of sgRNAs that specifically recognize the porcine CD163 gene and a set of vectors expressing the set of sgRNAs
[0066] 1. A set of sgRNAs that specifically recognize the porcine CD163 gene
[0067] The set of sgRNAs for specifically recognizing the porcine CD163 gene in the present invention consists of CD163-sgRNA1 and CD163-sgRNA2.
[0068] The nucleotide sequence of CD163-sgRNA1 is shown as SEQ ID No.5, wherein the nucleotide sequence responsible for identifying the target fragment is shown as SEQ ID No.1, and the target sequence of CD163-sgRNA1 is shown as SEQ ID No.3. The target sequence shown in SEQ ID No.3 is located at positions 131-150 of the seventh exon of the pig CD163 gene.
[0069] The nucleotide sequence of CD163-sgRNA2 is shown in SEQ ID No.6, wherein the nucleotide sequence responsible for identifying the target fragment is shown in SEQ ID No.2, and the target sequence of CD163-sgRNA2 is shown in SEQ ID No.4. The target sequence shown in SEQ ID No.4 is located at positions 265-284 of the seventh exon of the pig CD163 gene.
[0070] 2. Preparation of a set of vectors expressing a set of sgRNAs
[0071] 1. Preparation of double-stranded DNA fragments
[0072] Oligonucleotide DNA sequences were designed according to the sgRNA targeting sequence and sent to Beijing Tianyi Huiyuan Biotechnology Co., Ltd. for synthesis (1 OD per synthesis, and PAGE was selected for purification). The specific sequences are as follows:
[0073] CD163-sgRNA1-F:AAACACCGGGAACTACAGTGCGGCACTG;
[0074] CD163-sgRNA1-R: CTCTAAAACCAGTGCCGCACTGTAGTTCC;
[0075] CD163-sgRNA2-F:AAACACCGGCTACATGTCCCGTCAGGGC;
[0076] CD163-sgRNA2-R: CTCTAAAACGCCCTGACGGGACATGTAGC.
[0077] CD163-sgRNA1-F and CD163-sgRNA1-R were annealed to form a double-stranded DNA fragment 1 with sticky ends.
[0078] CD163-sgRNA2-F and CD163-sgRNA2-R were annealed to form a double-stranded DNA fragment 2 with sticky ends.
[0079] 2. Preparation of a set of vectors expressing a set of sgRNAs
[0080] The double-stranded DNA fragment 1 with sticky ends was inserted into the Bbs I restriction site of the pX330 vector (Addgene, 42230) to obtain the pX330-CD163-sgRNA1 vector. The pX330-CD163-sgRNA1 vector expresses the CD163-sgRNA1 and Cas9 proteins shown in SEQ ID No. 5.
[0081] The double-stranded DNA fragment 2 with sticky ends was inserted into the Bbs I restriction site of the pX330 vector (Addgene, 42230) to obtain the pX330-CD163-sgRNA2 vector. The pX330-CD163-sgRNA2 vector expresses the CD163-sgRNA2 and Cas9 proteins shown in SEQ ID No.6.
[0082] The target sequence shown in SEQ ID No.3 was cloned into the pX330-GFP (ViewSolid Biotech, VK001-02) vector with a GFP screening marker according to the kit instructions to obtain the pX330-GFP-CD163-sgRNA1 vector. The pX330-GFP-CD163-sgRNA1 vector expresses the CD163-sgRNA1 and Cas9 proteins shown in SEQ ID No.5.
[0083] The target sequence shown in SEQ ID No.4 was cloned into the pX330-RFP (ViewSolid Biotech, VK001-04) vector with RFP screening marker according to the kit instructions to obtain the pX330-RFP-CD163-sgRNA2 vector. The pX330-RFP-CD163-sgRNA2 vector expresses the CD163-sgRNA2 and Cas9 proteins shown in SEQ ID No.6.
[0084] Example 2: Preparation of CD163 gene-edited immortalized porcine alveolar macrophages and anti-PRRSV infection detection using a complete vector set mediated by the Cas9 system
[0085] 1. Preparation of CD163 gene-edited iPAM cells
[0086] 1×10 cells were co-transfected with 5 μg of pX330-GFP-CD163-sgRNA1 vector and 5 μg of pX330-RFP-CD163-sgRNA2 vector using the Lonza 2B nuclear transfection system and the accompanying transfection kit (Lonza, VPI-1002). 6 iPAM cells were prepared. The transfection steps were detailed in the instructions of the kit to obtain transfected iPAM cells.
[0087] 48h after cell transfection, flow sorting was performed, monoclonal cells were cultured, and genotype identification was performed on the monoclonal cells to obtain iPAM cells with 120bp precise fragment deletion of CD163 gene and expand the culture. Two different clones of iPAM cells with 120bp precise fragment deletion of CD163 gene were recorded as iPAM-107 and iPAM-120 respectively. Compared with wild-type iPAM cells, the difference between iPAM cells with 120bp precise fragment deletion of CD163 gene (iPAM-107 and iPAM-120) was only that the two homologous chromosomes in the seventh exon of pig CD163 gene had a 120bp fragment deletion, and the deletion fragment was the base sequence shown in the 148th-267th position of SEQID No.9.
[0088] II. Anti-PRRSV infection experiment of iPAM cells with 120bp precise deletion of CD163 gene
[0089] iPAM cells with a precise deletion of 120 bp of the CD163 gene were seeded into 48-well plates one day before infection, and the iPAM cells were infected with PRRSV-WUH3 at a multiplicity of infection of 0.5.
[0090] 1. Collect cells 24 hours after infection, wash with PBS 4-5 times, extract RNA, and use qRT-PCR to detect the number of PRRSV virus copies in cells.
[0091] The qRT-PCR test results are as follows Figure 1 As shown, the results showed that the PRRSV genomic RNA copy number in iPAM cells with precise deletion of 120bp fragment of CD163 gene was significantly reduced compared with wild-type iPAM cells (***P<0.001).
[0092] 2. After 24 hours of infection, cells were collected, cell proteins were extracted, and the expression of CD163 and PRRSV-N proteins was detected by Western Blot.
[0093] Western Blot test results Figure 2 As shown, the results showed that CD163 was normally expressed in both wild-type iPAM cells and iPAM cells with a precise 120bp fragment deletion of the CD163 gene; and PRRSV-N protein was abundantly expressed in wild-type iPAM cells, while the expression of PRRSV-N protein was not detected in iPAM cells with a precise 120bp fragment deletion of the CD163 gene.
[0094] 3. Collect cells 24 hours after infection and use IFA to detect the expression of PRRSV-N in cells.
[0095] IFA test results Figure 3 As shown, the results showed that after the wild-type iPAM cells were inoculated with the virus, the cells were heavily infected with PRRSV; while the iPAM cells with a precise 120bp fragment deletion of the CD163 gene could not be detected with PRRSV infection.
[0096] The above results show that compared with wild-type iPAM cells, iPAM cells with a precise 120bp deletion of the CD163 gene can completely resist PRRSV infection.
[0097] Example 3. Detection of editing efficiency of porcine fetal fibroblast CD163 gene by a complete vector set mediated by Cas9 system
[0098] 1. Transfection of porcine fetal fibroblasts
[0099] 1×10 5 μg of pX330-CD163-sgRNA1 vector and pX330-CD163-sgRNA2 vector prepared in Example 1 were co-transfected using the Lonza 2B nuclear transfection system and the matching transfection kit (Lonza, VPI-1002). 6 The transfection steps are detailed in the instructions of the kit to obtain transfected porcine fetal fibroblasts.
[0100] 2. Editing efficiency and deletion efficiency detection
[0101] 48 hours after cell transfection, the genomic DNA of transfected porcine fetal fibroblasts was extracted using the BioTeke Cell / Tissue Genomic DNA Extraction Kit (spin column type, catalog number DP1902). Using the extracted genomic DNA as a template, PCR amplification was performed using the primers CD163-406-F2 and CD163-406-R2 using Premix Taq DNA polymerase to obtain PCR products. The primer sequences are as follows:
[0102] CD163-406-F2: 5'-TCCCTCACCGAAATGCTAT-3' (SEQ ID No. 10);
[0103] CD163-406-R2: 5'-TGACTACCTAACCCTACCCTCT-3' (SEQ ID No. 11).
[0104] PCR amplification conditions were: 95°C for 5 min; 95°C for 30 s, 62°C for 30 s, 72°C for 30 s, 34 cycles; 72°C for 5 min.
[0105] After purification, the PCR product was connected to the T vector. After the connection product was transformed into Escherichia coli, monoclonal colonies were cultured. Single colonies were picked for sequencing, and the total editing efficiency, fragment deletion efficiency and precise fragment deletion efficiency after sequencing were calculated.
[0106] Total editing efficiency = number of mutant clones / total number of clones.
[0107] Fragment deletion efficiency = number of fragment deleted clones / total number of clones.
[0108] The efficiency of accurate fragment deletion = the number of clones with accurate fragment deletion / the total number of clones.
[0109] Among them, mutant clones refer to monoclonal clones with mutations in the CD163 gene sequence; fragment deletion clones refer to monoclonal colonies with fragment deletion mutations in the CD163 gene sequence under the action of double sgRNA; precise fragment deletion clones refer to monoclonal colonies with deletion mutations in the CD163 gene sequence of 120bp fragment (corresponding to the 148-267 base sequence of SEQ ID No.9).
[0110] The genotypes of some edited cells are as follows Figure 4 The editing efficiency is shown in Table 1.
[0111] Table 1. Statistical results of CD163 gene editing efficiency in porcine fetal fibroblasts
[0112]
[0113] Example 4. Preparation of CD163 gene-edited pigs using somatic cell nuclear transfer technology
[0114] The homozygous gene-edited positive cells obtained in Example 3 were used as nuclear transplant donor cells, and the enucleated pig oocytes matured in vitro for 40 hours were used as nuclear transplant recipient cells. The nuclear transplant donor cells were transferred into the oocytes, and after electrical fusion and activation, recombinant cloned embryos were constructed. The cloned recombinant embryos with good development status were selected and surgically transferred into the uterus of a naturally estrus multiparous large white sow for pregnancy. The surgical embryo transplantation steps were as follows: the recipient sow was intravenously injected with Zoletil anesthetic for induction anesthesia, and the injection dose was 5 mg / kg body weight. After anesthesia, the recipient sow was moved to the surgical frame for supine restraint and respiratory anesthesia (isoflurane concentration was 3% to 4%). A surgical incision about 10 cm long was made on the midline of the abdomen of the recipient sow to expose the ovaries, fallopian tubes and uterus. The embryo transplantation glass tube was used to enter about 5 cm along the fimbria of the fallopian tube, and the cloned recombinant embryos with good development status were transplanted to the junction of the ampulla-isthmus of the fallopian tube. After embryo transplantation, the technicians observed regularly and checked the pregnancy of the recipient sows with B-type ultrasound. After the piglets were born, ear tissues were cut and genomic DNA was extracted. PCR amplification was performed using CD163-406-F2 and CD163-406-R2, and the PCR amplification products were sequenced to detect the genotype.
[0115] The present invention has been described in detail above. It will be apparent to those skilled in the art that the present invention may be implemented in a wide range under equivalent parameters, concentrations and conditions without departing from the spirit and scope of the present invention and without the need for unnecessary experimentation. Although the present invention provides specific embodiments, it should be understood that further improvements may be made to the present invention. In short, according to the principles of the present invention, this application intends to include any changes, uses or improvements to the present invention, including changes made by conventional techniques known in the art that depart from the scope disclosed in this application. Applications of some of the basic features may be made within the scope of the following appended claims.
Claims
1. A set of sgRNAs, including CD163-sgRNA1 and CD163-sgRNA2; The nucleotide sequence responsible for identifying the target fragment in the CD163-sgRNA1 is shown in SEQ ID No. 1; The nucleotide sequence responsible for recognizing the target fragment in the CD163-sgRNA2 is shown in SEQ ID No.
2.
2. The set of sgRNA according to claim 1, characterized in that: The nucleotide sequence of the CD163-sgRNA1 is shown in SEQ ID No.5; The nucleotide sequence of the CD163-sgRNA2 is shown in SEQ ID No.
6.
3. A set of DNA molecules, including a DNA molecule encoding CD163-sgRNA1 and a DNA molecule encoding CD163-sgRNA2; The DNA molecule encoding the CD163-sgRNA1 contains the DNA molecule shown in SEQ ID No.3; The DNA molecule encoding the CD163-sgRNA2 contains the DNA molecule shown in SEQ ID No.
4.
4. The set of DNA molecules according to claim 3, characterized in that: The DNA molecule encoding the CD163-sgRNA1 is shown in SEQ ID No.7; The DNA molecule encoding the CD163-sgRNA2 is shown in SEQ ID No.
8.
5. A complete set of vectors, including a vector expressing CD163-sgRNA1 and a vector expressing CD163-sgRNA2; The vector expressing CD163-sgRNA1 is a vector containing a DNA molecule encoding CD163-sgRNA1 according to claim 3 or 4; The vector expressing CD163-sgRNA2 is a vector containing the DNA molecule encoding CD163-sgRNA2 according to claim 3 or 4.
6. A kit comprising the set of sgRNAs according to claim 1 or 2, or the set of DNA molecules according to claim 3 or 4, or the set of vectors according to claim 5.
7. The kit according to claim 6, characterized in that: The kit also includes a Cas9 protein or biological materials associated with the Cas9 protein.
8. Use of the set of sgRNAs according to claim 1 or 2, or the set of DNA molecules according to claim 3 or 4, or the set of vectors according to claim 5, or the kit according to claim 6 in any of the following 1)-5): 1) CD163 gene editing in the pig genome; 2) Prepare products for CD163 gene editing in the pig genome; 3) Preparation of CD163 gene-edited pig-derived cells; 4) Preparation of CD163 gene-edited pigs; 5) Breed pig breeds that are resistant to PRRSV infection.
9. Any of the following methods A1)-A8): A1) A method for CD163 gene editing in a pig genome, comprising the step of introducing the set of sgRNAs described in claim 1 or 2 or the set of vectors described in claim 5 and the Cas9 protein into a pig-derived biomaterial; A2) A method for preparing CD163 gene-edited pig-derived cells, comprising the step of introducing the set of sgRNAs described in claim 1 or 2 or the set of vectors described in claim 5 and the Cas9 protein into pig-derived cells; A3) A method for preparing a CD163 gene-edited pig, comprising the step of introducing the set of sgRNAs described in claim 1 or 2 or the set of vectors described in claim 5 and the Cas9 protein into a pig-derived biomaterial; A4) A method for preparing a pig breed resistant to PRRSV infection, comprising the step of introducing the set of sgRNAs according to claim 1 or 2 or the set of vectors and Cas9 protein according to claim 5 into a pig-derived biological material; A5) a method for editing the CD163 gene in the pig genome, comprising the step of deleting the base sequence of position 148-267 of the seventh exon of the pig CD163 gene in the pig-derived biological material; A6) A method for preparing CD163 gene-edited pig-derived cells, comprising the step of deleting the base sequence at positions 148-267 of the seventh exon of the pig CD163 gene in the pig-derived cells; A7) A method for preparing a CD163 gene-edited pig, comprising the step of deleting the base sequence at positions 148-267 of the seventh exon of the pig CD163 gene in a pig-derived biological material; A8) The preparation method of the pig variety that resists PRRSV infection comprises the step of deleting the base sequence of position 148-267 of the seventh exon of the pig CD163 gene in the pig source biological material.
10. The use according to claim 8 or the method according to claim 9, characterized in that: The CD163 gene is the seventh exon of the CD163 gene.
Citation Information
Cited By
Reagent and method for editing pig CD71 gene
CN120290556A
